New Canadian Trials Explore Potential of Fecal Microbiota Transplant Tablets in Cancer Treatment
Recent research highlights the importance of medicine in tackling complex health issues. Two Canadian clinical trials suggest that fecal microbiota transplant (FMT) tablets, colloquially known as “poop pills,” might mitigate some toxic side effects of cancer therapies and even enhance patient responses to immunotherapy.
These FMT tablets consist of freeze-dried feces. A study shared in Nature Medicine hints that these capsules could substantially improve cancer treatment outcomes.
In an initial phase of research, experts from the London Health Sciences Center Research Institute and the Lawson Institute investigated the safety of FMT used alongside immunotherapy drugs aimed at kidney cancer treatment.
After evaluating data from 20 patients, the team discovered that tailored FMT could lessen some severe side effects linked to immunotherapy.
“Current treatments for advanced kidney cancer often incorporate immunotherapy drugs to aid the body’s immune response against cancer cells,” noted LHSCRI scientist Saman Maleki. However, he pointed out that such treatments can lead to issues like colitis and significant diarrhea, which may force patients to discontinue essential life-saving therapies prematurely. Reducing these adverse effects could really change the game for many patients.
In a subsequent phase of the trials, researchers from the Center Université Hospital de Montréal examined whether FMT could improve how lung cancer and melanoma patients respond to immunotherapy.
The findings were remarkable: 80% of lung cancer patients who underwent FMT responded positively to immunotherapy, compared with just 39% to 45% of those treated without it. Similarly, 75% of melanoma patients receiving FMT also showed a favorable response, in contrast to 50-58% for those without the treatment.
“Our clinical trial contributes to the understanding that fecal microbiota transplantation can boost the effectiveness of immunotherapy for lung cancer and melanoma patients,” stated Dr. Ariel Elkrief, co-principal investigator and medical scientist at CRCHUM.
Part of the success of FMT may stem from its ability to eliminate harmful bacteria, suggesting that these insights might pave the way for personalized microbiome therapies.
Both trials utilized FMT capsules developed by Lawson in London, Ontario, sourced from healthy donors’ stool, which, when ingested, helps restore balance to the gut microbiome.
“The prospect of using FMT to lessen drug toxicity, enhance clinical responses, and improve quality of life for cancer patients is significant. It’s a groundbreaking step in treating kidney cancer,” commented the study authors.
Further FMT investigations are in progress to determine its potential benefits for patients with pancreatic cancer and triple-negative breast cancer.
Ultimately, the hope is that such research will assist cancer patients in living longer while mitigating damaging side effects from their treatments, as Dr. Ricardo Fernandez emphasized.
Though unconventional, FMT isn’t entirely a new concept; it has been practiced in humans since 1958 and has a history spanning about a century in animal treatments.
In 2022, the Food and Drug Administration approved FMT as a therapy for severe infections caused by Clostridium difficile, a bacterium that can lead to symptoms like fever and diarrhea.
This form of treatment is also under investigation for various conditions, including ulcerative colitis and Crohn’s disease, and is being explored as a possible “anti-aging” intervention.
